Regeneron Pharmaceuticals, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Regeneron is an integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines. The filing covers the three months ended March 31, 2023, compared with the three months ended March 31, 2022. Key commercial products include EYLEA, Dupixent, Libtayo, Praluent, Evkeeza, Inmazeb, and collaboration products marketed with Sanofi, Bayer, and Roche.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $3,162.1 million | $2,965.1 million | 6.6% increase |
| Net product sales | $1,668.0 million | $1,638.6 million | 1.8% increase |
| Collaboration revenue | $1,378.1 million | $1,232.5 million | 11.8% increase |
| Income from operations | $946.7 million | $1,258.5 million | 24.8% decrease |
| Net income | $817.8 million | $973.5 million | 16.0% decrease |
| Diluted earnings per share | $7.17 | $8.61 | 16.7% decrease |
| Operating margin | 29.9% | 42.4% | Down 12.5 percentage points |
| Net margin | 25.9% | 32.8% | Down 6.9 percentage points |
| Cash flow from operations | $1,367.6 million | $2,101.7 million | 35.0% decrease |
Revenue growth was driven primarily by higher Sanofi collaboration revenue, including the Company’s share of Dupixent and Kevzara profits, and higher Libtayo sales following the transfer of worldwide rights. This was partly offset by lower U.S. and international EYLEA sales and the absence of a $50.0 million Sanofi sales milestone recognized in Q1 2022.
Products and collaboration activity
- EYLEA global net product sales declined 4% to $2,280.9 million; U.S. net product sales declined 6% to $1,433.8 million, primarily because of increased sales-related deductions.
- Dupixent global net product sales increased 37% to $2,485.0 million. Regeneron’s share of Dupixent and Kevzara collaboration profits increased to $636.5 million from $415.3 million, before development-cost reimbursement.
- Libtayo global net product sales increased 46% to $182.6 million. Regeneron now records worldwide Libtayo sales and pays Sanofi an 11% royalty on net sales through March 31, 2034.
- Roche collaboration revenue increased to $222.2 million from $216.3 million, reflecting the Company’s share of profits from Ronapreve sales.
- In March 2023, Regeneron entered a Sonoma Biotherapeutics collaboration, expensing a $45.0 million up-front payment as acquired in-process research and development. Sonoma may receive a $45.0 million development milestone.
Expenses, cash flow, debt, and liquidity
- Total operating expenses rose $508.8 million, or 29.8%, to $2,215.4 million. Research and development increased 30.5% to $1,101.2 million, while selling, general, and administrative expense increased 33.6% to $601.1 million.
- Expense increases reflected higher headcount and commercialization costs, expanded development activity, increased responsibility for Libtayo, changes to Sanofi cost-sharing arrangements, and higher stock-based compensation.
- Cash provided by operations was $1,367.6 million. Investing cash outflows were $235.7 million, including $178.2 million of capital expenditures and $100.9 million paid for Libtayo-related contingent consideration. Financing cash outflows were $322.5 million, primarily due to $710.7 million of share repurchases.
- Cash and cash equivalents were $3,916.3 million at March 31, 2023. Current and noncurrent marketable securities totaled $11,110.0 million, providing total cash and marketable securities of approximately $15.0 billion.
- Working capital was $13,809.1 million. Long-term debt was $1,981.8 million and finance lease liabilities were $720.0 million. The Company also had $750.0 million available under a revolving credit facility.
- Regeneron repurchased approximately 0.9 million shares for $693.9 million during the quarter. Approximately $3.051 billion remained available under its repurchase programs at March 31, 2023.
- Management expects 2023 capital expenditures of approximately $800 million to $900 million, primarily for Tarrytown and Rensselaer campus and manufacturing expansion, including a fill/finish facility.
Material changes versus the prior comparable period
- Revenue increased, but profitability declined because operating expenses grew substantially faster than revenue.
- The effective tax rate decreased to 4.7% from 8.3%, primarily due to stock-based compensation effects and income earned in lower-tax jurisdictions.
- Other expense declined to $88.7 million from $197.4 million, mainly because unrealized losses on equity securities decreased, while interest income increased materially.
- Operating cash flow declined by $734.1 million, partly because the prior-year period benefited from a $1,197.5 million reduction in accounts receivable compared with a $210.1 million reduction in Q1 2023.
- Stock-based compensation increased to $238.7 million from $166.9 million, and average headcount increased to 12,099 from 10,492.
Guidance, outlook, commentary, and risks
- Management expects continued substantial research and development and commercialization spending. Future profitability and operating cash flow depend significantly on EYLEA and Dupixent, collaboration economics, regulatory approvals, and successful commercialization of pipeline products.
- Aflibercept 8 mg had an FDA target action date of June 27, 2023, with potential U.S. approval for wet AMD, DME, and DR. Management also identified multiple 2023 pipeline milestones, including regulatory submissions and clinical readouts for Dupixent, odronextamab, linvoseltamab, and other candidates.
- The Company reported positive Phase 3 COPD results for Dupixent in patients with evidence of type 2 inflammation, but a Phase 3 trial in chronic cold-induced urticaria did not meet required efficacy endpoints.
- EYLEA remains a major concentration risk: U.S. EYLEA sales represented 45% of total revenue in Q1 2023. U.S. biologic regulatory exclusivity expires after May 17, 2024, creating potential biosimilar pressure. The commercial impact of aflibercept 8 mg, if approved, remains uncertain.
- Material risks include reimbursement and pricing pressure, competition, regulatory and clinical-development uncertainty, manufacturing and supply-chain constraints, collaboration dependence, intellectual-property litigation, and government investigations concerning patient assistance, sales and marketing practices, and EYLEA pricing and reimbursement.
- Pending matters include patent litigation involving Praluent, EYLEA, EYLEA pre-filled syringe, and REGEN-COV, as well as Department of Justice and payor-related proceedings. Accrued legal loss contingencies were not material as of March 31, 2023, although certain reasonably possible losses were not estimable.
- The Company stated that its disclosure controls and procedures were effective as of March 31, 2023 and that there were no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Assess the sustainability of Dupixent-driven collaboration revenue and the impact of the increased Sanofi development-cost reimbursement percentage.
- Track EYLEA U.S. sales deductions, competitive share, biosimilar launches, patent outcomes, and the regulatory and commercial progress of aflibercept 8 mg.
- Reconcile the expected $800 million–$900 million of 2023 capital expenditures with operating cash generation and planned manufacturing expansion.
- Monitor the effect of higher research, development, commercialization, headcount, and stock-based compensation costs on operating margins.
- Review the outcomes and potential financial exposure from the EYLEA, Praluent, REGEN-COV, patient-assistance, and EYLEA pricing-related legal and government matters.
- Verify collaboration continuity and economics with Sanofi, Bayer, and Roche, including termination rights, royalties, reimbursement obligations, and reliance on partners for international commercialization.